As of today (2022-05-23), Orgenesis's share price is $2.10.
Orgenesis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $-1.43. Hence, Orgenesis's Price-to-Free-Cash-Flow Ratio for today is .
The historical rank and industry rank for Orgenesis's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 3.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -34.30% per year.
During the past 13 years, Orgenesis's highest 3-Year average Free Cash Flow per Share Growth Rate was 3.40% per year. The lowest was -519.30% per year. And the median was -37.60% per year.
Orgenesis Price-to-Free-Cash-Flow Historical Data
The historical data trend for Orgenesis's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Price-to-Free-Cash-Flow
-
-
-
-
-
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Price-to-Free-Cash-Flow
-
-
-
-
-
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Price-to-Free-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Orgenesis's Price-to-Free-Cash-Flow falls into.
Orgenesis Price-to-Free-Cash-Flow Calculation
Orgenesis's Price-to-Free-Cash-Flow ratio for today is calculated as
Orgenesis's Share Price of today is $2.10.
Orgenesis's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Orgenesis Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Orgenesis's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 44,682 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
